Revive Therapeutics Ltd - RVVTF STOCK NEWS

Revive Therapeutics provides an update on a clinical study evaluating oral psilocybin for methamphetamine use disorder. The study shows promising initial efficacy, with potential for future commercial initiatives and exclusive access to valuable intellectual property.

Revive Therapeutics submits Type C meeting request package to FDA for evaluation of Bucillamine as a potential treatment for long-term COVID. The Company aims to address long COVID symptoms and potential economic costs through leveraging previous clinical trial data.

Revive Therapeutics announced that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine as a potential treatment for long COVID. The Company expects to submit the request soon. Bucillamine has shown promise in previous studies for COVID-19 treatment, and research suggests its potential for long COVID. These developments could have significant implications for medical treatment and the economic impact of long COVID.

Revive Therapeutics Ltd. provides a corporate update on research initiatives with Bucillamine for long COVID and nerve agent exposure. The company aims to develop Bucillamine as a treatment for nerve agent exposure and explore its potential for long COVID. Additionally, Revive is advancing the development of a blood biomarker diagnostic for long COVID.

Revive Therapeutics Ltd. announced its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The company aims to advance the clinical development of Bucillamine by leveraging existing data from its previous Phase 3 clinical trial and is preparing a clinical package for presentation to the FDA and international health regulatory bodies. The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms, and the economic cost could be as much as $3.7 trillion. The results of the Study evaluating the safety and efficacy of oral Bucillamine in patients with mild to moderate COVID-19 showed promising outcomes, with no deaths and a low hospitalization rate. Thiol-based drugs like Bucillamine have shown potential in inhibiting SARS-CoV-2 cell entry and live virus infection, providing a rationale for testing them as a novel treatment for COVID-19.

Revive Therapeutics Ltd. announced an update on the project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada. The research protocol has been finalized, and the project is expected to be completed by the end of Q2-2024. Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors. The results from this research, if promising, will determine further studies to facilitate Health Canada approval for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and potentially begin initial studies for efficacy against mild traumatic brain injury caused by concussive or explosive forces.

Revive Therapeutics Ltd. (RVVTF) completes the formulation development work of its next-generation lyophilized formulation of Bucillamine, with potential applications in treating public health medical emergencies. The new formulation has the potential to increase Bucillamine delivery per dosing unit and create a parenteral injection product with minimal formulation additives. Revive plans to evaluate the new formulation in a clinical study this year and expects to have it ready for clinical evaluation in 2024.

Revive Therapeutics Ltd. (RVVTF) announces successful annual general and special meeting of shareholders, re-elects Board of Directors, and approves 10% rolling stock option plan.

Revive Therapeutics Ltd. (RVVTF) has signed a collaboration agreement with Attwill Medical Solutions LP for the clinical and commercial development of its next-generation lyophilized formulation of Bucillamine. The collaboration aims to support the technology transfer of the formulation from the University of Waterloo to AMS, with expectations of clinical evaluation in 2024. The novel lyophilized Bucillamine may have potential applications in treating nerve agent exposure and rare inflammatory disorders, with the FDA granting orphan drug designation for ischemia-reperfusion injury in 2022.